Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical
trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic
steatohepatitis (NASH).